Discover 1,900 paid clinical trials in Virginia. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Virginia provides numerous opportunities for both healthy volunteers and people with specific medical conditions to participate in paid medical research. Major research centers in Richmond, Virginia Beach, and Norfolk are actively seeking participants, offering access to innovative treatments and advanced care.
Filter
1
Filter results
Results: 1,900
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
for
Locally Advanced or Metastatic Solid Tumors
Location: Lake Success NY, Fairfax VA
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07730021
Phase 1, Phase 2, Recruiting
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
for
Metastatic Colorectal Adenocarcinoma,
Location: Richmond VA, Charlottesville VA, Columbus OH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06102902
Phase 1, Recruiting
Kamuvudine-9 (K9) in Diabetic Macular Edema
for
Diabetic Macular Edema
Location: Roanoke VA
Sponsor: Dr. Bryan Strelow
Sex: All
Age: 18+
Code: NCT07458061
Phase 1, Phase 2, Recruiting
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: West Palm Beach FL, Roanoke VA, Orlando FL,
Sponsor: Bicara Therapeutics
Sex: All
Age: 18+
Code: NCT07807163
Phase 2, Recruiting
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
for
Metastatic Malignant Neoplasm
Location: The Bronx NY, Baltimore MD, Fairfax VA, Nashville TN,
Sponsor: NextPoint Therapeutics, Inc.
Sex: All
Age: 19+
Code: NCT07563829
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
for
Heart Failure
Location: New York NY, Hershey PA, Charlottesville VA,
Sponsor: EBR Systems, Inc.
Sex: All
Age: 22+
Code: NCT07098858
Recruiting
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.
for
Ankle Arthrodesis or Arthroplasty, Hindfoot Fusion,
Location: Philadelphia PA, Falls Church VA, Charlotte NC,
Sponsor: Kuros Biosurgery AG
Sex: All
Age: 18 - 70+
Code: NCT07225751
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
for
Pulmonary Hypertension, Interstitial Lung Disease
Location: New York NY, Philadelphia PA, Richmond VA, Durham NC,
Sponsor: Insmed Incorporated
Sex: All
Age: 18+
Code: NCT07179380
Phase 3, Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
for
Non-Small Cell Lung Cancer
Location: Boston MA, Mineola NY, New York NY, Philadelphia PA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07100080
Phase 2, Phase 3, Recruiting
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
for
Selected Types of Solid Tumor
Location: New York NY, Fairfax VA, Houston TX
Sponsor: Everest Medicines (Beijing) Co., Ltd.
Sex: All
Age: 18+
Code: NCT07095868
Phase 1, Phase 2, Recruiting
Cardiorespiratory Fitness, Handgrip Strength, and Cardiometabolic Health in Obese Children With or Without Autism Spectrum Disorder: a Retrospective Cohort Study
for
Autism Spectrum Disorder (ASD),
Location: Charlottesville VA
Sponsor: University of Virginia
Sex: All
Age: 6 - 18
Code: NCT07804680
Recruiting
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
for
Clear Cell Renal Cell Carcinoma,
Location: Charlottesville VA, Gainesville FL, Oklahoma City OK,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07516366
Phase 2, Recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
for
Type 2 Diabetes
Location: Morehead City NC, Burke VA, Miami Lakes FL,
Sponsor: Biomea Fusion Inc.
Sex: All
Age: 18 - 70+
Code: NCT07502508
Phase 2, Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Location: New York NY, New Brunswick NJ, Morristown NJ,
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT04913285
Phase 1, Recruiting
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
for
Uncontrolled Hypertension
Location: Boston MA, Methuen MA, Waterbury CT, The Bronx NY,
Sponsor: Retension Pharmaceuticals. Inc.
Sex: All
Age: 18 - 70+
Code: NCT07142356
Phase 2, Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
for
B-cell Lymphoma, Chronic Lymphocytic Leukemia,
Location: Fairfax VA, Macon GA, Fort Wayne IN, Indianapolis IN,
Sponsor: Nurix Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07516093
Phase 3, Recruiting
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
for
Obesity, Overweight
Location: Morehead City NC, Newport News VA, New Bern NC,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT07752979
Phase 2, Recruiting
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
for
Locally Advanced Adrenal Cortical Carcinoma,
Location: Boston MA, Commack NY, Uniondale NY, Harrison NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 12+
Code: NCT06900595
Phase 2, Recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400